Tang Kevin C's Form 4 filing
Jounce Therapeutics, Inc. (JNCE) · filed Mar 14, 2023
- Accession no.
- 0001209191-23-018721
- Filed
- Mar 14, 2023, 8:39 PM ET
- Trade date
- Mar 13-14, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $86.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tang Kevin CCIK 0001178579 | 10% Owner |
| Tang Capital Partners LPCIK 0001191935 | 10% Owner |
| Tang Capital Management LLCCIK 0001232621 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 herein.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.02.
Referenced by the price of 1 transaction in Table I.